Cases reported by Dhangar et al. [14] and Wakim et al. [19] illustrate the variable efficacy of sorafenib, a multikinase inhibitor able to inhibit FGFR1, in treating leukemia with the BCR::FGFR1 rearrangement [49]. The gene discussed is FGFR1; the disease is leukemia.